Christina completed her Master of Science in Biotechnology at the University of Muenster, Germany, in 2018. In 2022, she earned her PhD at the Kirby Institute, University of New South Wales, Sydney, where her research focused on developing transient lentivirus-based delivery systems for gene therapy.
Her work centered on achieving the delivery of CRISPR/Cas9 RNPs and biologically active mRNA to resting CD4+ T cells, a notoriously hard to transduce cell population. In September 2024, Christina joined the Translational Vectorology Research Unit, applying her expertise in lentiviral vector design and production toward developing a gene therapy for Parkinson’s Disease.
Christina Fichter
Research Officer
Email
[email protected]